Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Mallinckrodt
Healthtrust
Daiichi Sankyo
Cantor Fitzgerald
Deloitte
Cerilliant
Covington

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,299,900

« Back to Dashboard

Summary for Patent: 6,299,900
Title: Dermal penetration enhancers and drug delivery systems involving same
Abstract:A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterized in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
Inventor(s): Reed; Barry Leonard (Strathmore, AU), Morgan; Timothy Matthias (Parkville, AU), Finnin; Barrie Charles (Glen Iris, AU)
Assignee: Monash University (Victoria, AU)
Application Number:09/125,436
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,299,900
Patent Claim Types:
see list of patent claims
Delivery; Compound; Use; Device;

Drugs Protected by US Patent 6,299,900

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,299,900

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPN 8144Feb 19, 1996
PCT Information
PCT FiledFebruary 19, 1997PCT Application Number:PCT/AU97/00091
PCT Publication Date:August 21, 1997PCT Publication Number: WO97/29735

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKesson
Moodys
UBS
Colorcon
Teva
Chubb
Harvard Business School
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.